These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15291357)

  • 21. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Disappearance of residual disease confirmed by RT-PCR following induction chemotherapy in two hypoplastic leukemia patients with t(8;21)].
    Sawada M; Tsurumi H; Yamada T; Hara T; Oyama M; Moriwaki H
    Rinsho Ketsueki; 1999 Apr; 40(4):311-7. PubMed ID: 10355140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
    Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia.
    Garg M; Moore H; Tobal K; Liu Yin JA
    Br J Haematol; 2003 Oct; 123(1):49-59. PubMed ID: 14510942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
    Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
    Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
    Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
    Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
    Miyamura T; Sakata N; Okamura T; Yasui M; Inoue M; Yagi K; Sako M; Komada Y; Matsuyama T; Oda M; Park YD; Kawa K
    Int J Hematol; 2004 Apr; 79(3):243-9. PubMed ID: 15168592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance of detection of AML1/ETO fusion transcripts in childhood AML using real-time quantitative reverse transcription polymerase chain reaction].
    Liu CF; Liu GL; Zhang LP; Cheng YF; Lu AD; Tian KG; Liu YR; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):76-82. PubMed ID: 15748440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
    Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
    Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR.
    Tobal K; Liu Yin JA
    Methods Mol Med; 2006; 125():149-61. PubMed ID: 16502583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay.
    Muto A; Mori S; Matsushita H; Awaya N; Ueno H; Takayama N; Okamoto S; Kizaki M; Ikeda Y
    Br J Haematol; 1996 Oct; 95(1):85-94. PubMed ID: 8857943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia.
    Miyamoto T; Nagafuji K; Harada M; Eto T; Fujisaki T; Kubota A; Akashi K; Mizuno S; Takenaka K; Kanaji T
    Br J Haematol; 1995 Sep; 91(1):132-8. PubMed ID: 7577620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
    Abdel Rahman H; Farrag SA; El-Attar IA
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):39-47. PubMed ID: 18839034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR.
    Tobal K; Liu Yin JA
    Leuk Lymphoma; 1998 Sep; 31(1-2):115-20. PubMed ID: 9720721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.